These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 25081751)

  • 1. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
    Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
    Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.
    Xu J; Xu FP; Liu ZH; Cui Q; Zhang KP; Li Z
    Medicine (Baltimore); 2022 Jul; 101(29):e29668. PubMed ID: 35866817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
    Terzi NK; Yilmaz I; Oz AB
    Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
    Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
    Eckel-Passow JE; Lachance DH; Molinaro AM; Walsh KM; Decker PA; Sicotte H; Pekmezci M; Rice T; Kosel ML; Smirnov IV; Sarkar G; Caron AA; Kollmeyer TM; Praska CE; Chada AR; Halder C; Hansen HM; McCoy LS; Bracci PM; Marshall R; Zheng S; Reis GF; Pico AR; O'Neill BP; Buckner JC; Giannini C; Huse JT; Perry A; Tihan T; Berger MS; Chang SM; Prados MD; Wiemels J; Wiencke JK; Wrensch MR; Jenkins RB
    N Engl J Med; 2015 Jun; 372(26):2499-508. PubMed ID: 26061753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
    Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
    Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
    Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
    Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
    Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
    ; Brat DJ; Verhaak RG; Aldape KD; Yung WK; Salama SR; Cooper LA; Rheinbay E; Miller CR; Vitucci M; Morozova O; Robertson AG; Noushmehr H; Laird PW; Cherniack AD; Akbani R; Huse JT; Ciriello G; Poisson LM; Barnholtz-Sloan JS; Berger MS; Brennan C; Colen RR; Colman H; Flanders AE; Giannini C; Grifford M; Iavarone A; Jain R; Joseph I; Kim J; Kasaian K; Mikkelsen T; Murray BA; O'Neill BP; Pachter L; Parsons DW; Sougnez C; Sulman EP; Vandenberg SR; Van Meir EG; von Deimling A; Zhang H; Crain D; Lau K; Mallery D; Morris S; Paulauskis J; Penny R; Shelton T; Sherman M; Yena P; Black A; Bowen J; Dicostanzo K; Gastier-Foster J; Leraas KM; Lichtenberg TM; Pierson CR; Ramirez NC; Taylor C; Weaver S; Wise L; Zmuda E; Davidsen T; Demchok JA; Eley G; Ferguson ML; Hutter CM; Mills Shaw KR; Ozenberger BA; Sheth M; Sofia HJ; Tarnuzzer R; Wang Z; Yang L; Zenklusen JC; Ayala B; Baboud J; Chudamani S; Jensen MA; Liu J; Pihl T; Raman R; Wan Y; Wu Y; Ally A; Auman JT; Balasundaram M; Balu S; Baylin SB; Beroukhim R; Bootwalla MS; Bowlby R; Bristow CA; Brooks D; Butterfield Y; Carlsen R; Carter S; Chin L; Chu A; Chuah E; Cibulskis K; Clarke A; Coetzee SG; Dhalla N; Fennell T; Fisher S; Gabriel S; Getz G; Gibbs R; Guin R; Hadjipanayis A; Hayes DN; Hinoue T; Hoadley K; Holt RA; Hoyle AP; Jefferys SR; Jones S; Jones CD; Kucherlapati R; Lai PH; Lander E; Lee S; Lichtenstein L; Ma Y; Maglinte DT; Mahadeshwar HS; Marra MA; Mayo M; Meng S; Meyerson ML; Mieczkowski PA; Moore RA; Mose LE; Mungall AJ; Pantazi A; Parfenov M; Park PJ; Parker JS; Perou CM; Protopopov A; Ren X; Roach J; Sabedot TS; Schein J; Schumacher SE; Seidman JG; Seth S; Shen H; Simons JV; Sipahimalani P; Soloway MG; Song X; Sun H; Tabak B; Tam A; Tan D; Tang J; Thiessen N; Triche T; Van Den Berg DJ; Veluvolu U; Waring S; Weisenberger DJ; Wilkerson MD; Wong T; Wu J; Xi L; Xu AW; Yang L; Zack TI; Zhang J; Aksoy BA; Arachchi H; Benz C; Bernard B; Carlin D; Cho J; DiCara D; Frazer S; Fuller GN; Gao J; Gehlenborg N; Haussler D; Heiman DI; Iype L; Jacobsen A; Ju Z; Katzman S; Kim H; Knijnenburg T; Kreisberg RB; Lawrence MS; Lee W; Leinonen K; Lin P; Ling S; Liu W; Liu Y; Liu Y; Lu Y; Mills G; Ng S; Noble MS; Paull E; Rao A; Reynolds S; Saksena G; Sanborn Z; Sander C; Schultz N; Senbabaoglu Y; Shen R; Shmulevich I; Sinha R; Stuart J; Sumer SO; Sun Y; Tasman N; Taylor BS; Voet D; Weinhold N; Weinstein JN; Yang D; Yoshihara K; Zheng S; Zhang W; Zou L; Abel T; Sadeghi S; Cohen ML; Eschbacher J; Hattab EM; Raghunathan A; Schniederjan MJ; Aziz D; Barnett G; Barrett W; Bigner DD; Boice L; Brewer C; Calatozzolo C; Campos B; Carlotti CG; Chan TA; Cuppini L; Curley E; Cuzzubbo S; Devine K; DiMeco F; Duell R; Elder JB; Fehrenbach A; Finocchiaro G; Friedman W; Fulop J; Gardner J; Hermes B; Herold-Mende C; Jungk C; Kendler A; Lehman NL; Lipp E; Liu O; Mandt R; McGraw M; Mclendon R; McPherson C; Neder L; Nguyen P; Noss A; Nunziata R; Ostrom QT; Palmer C; Perin A; Pollo B; Potapov A; Potapova O; Rathmell WK; Rotin D; Scarpace L; Schilero C; Senecal K; Shimmel K; Shurkhay V; Sifri S; Singh R; Sloan AE; Smolenski K; Staugaitis SM; Steele R; Thorne L; Tirapelli DP; Unterberg A; Vallurupalli M; Wang Y; Warnick R; Williams F; Wolinsky Y; Bell S; Rosenberg M; Stewart C; Huang F; Grimsby JL; Radenbaugh AJ; Zhang J
    N Engl J Med; 2015 Jun; 372(26):2481-98. PubMed ID: 26061751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.